Sep 1, 2002
By:
Joanna Breitstein
A court's recent and unexpected decision to invalidate GlaxoSmithKline's (GSK) patent extension for market-leading antibiotic Augmentin (amoxicillin clavulanate) has competitors scrambling to grab its market share and position.
|
Promotional growth peaks in 2001, marketers hold their breath for 2002
Sep 1, 2002
By:
Joanna Breitstein
Pharma companies invested a hefty $12 billion in promoting to physicians and consumers in 2001, according to Scott-Levin. But after the highs of 2000, spending in 2001 seemed stunted-a growth rate of 9 versus 13 percent.
|
Sep 1, 2002
By:
Joanna Breitstein
Pharma companies may need to take a closer look at the way brand teams and corporations as a whole use competitive intelligence (CI)-across multiple functions-or they risk missing lucrative opportunities.
|
Sep 1, 2002
By:
Joanna Breitstein
Just a year shy of its 120th birthday, Dorland Global Health Communications is returning to its roots. As both the original and new name of the company, Dorland is contemporary yet sustains the agency's heritage, according to Rita Sweeney, president and COO.
|
Aug 1, 2002
By:
Joanna Breitstein
A majority of US television stations are using the same number of, or more, video news releases (VNR) and satellite media tours (SMT) to supplement health stories than they were one year ago, according to a recent survey conducted by DS Simon Productions, a media communications company. That is important news for pharma companies and their public relations partners, who are using those vehicles more than ever to communicate scientific research findings to consumer audiences.
|
Aug 1, 2002
By:
Joanna Breitstein
It's true that a PR pro's work is never done, but the Wall Street Journal is helping to make it easier. Agency execs can get a sneak peek at the next day's coverage by logging onto the newspaper's new online health-specific portal, Health Industry Edition, the night before.
|
Aug 1, 2002
By:
Joanna Breitstein
Pfizer's Florida: A Healthy State program will soon begin to analyze the effectiveness of its high blood pressure and Type 2 diabetes disease education programs.
|
Aug 1, 2002
By:
Joanna Breitstein
Like most large prospective clinical trials, the National Institutes of Health's arm of the Women's Health Initiative (WHI) raised more questions than it answered. In an effort to bring clarity to the "hormone debate," investigators evaluated the long-term effects of combined estrogen and progestin hormone therapy on menopausal women primarily in regard to heart disease, but also in regard to osteoporosis and breast and colon cancer.
|
Aug 1, 2002
By:
Joanna Breitstein
David Shulkin, MD, compares hospitals' current adoption of patient safety officers (PSO) to ten years ago, when healthcare systems began naming chief medical officers (CMO). As the first CMO of the University of Pennsylvania health system and the first appointed CMO of any academic medical center, Shulkin remembers the "slow and painful process" he and his colleagues experienced when undertaking new roles and how difficult it was to create everything-from job descriptions to definitions of success-from scratch.
|
|
PharmExec Blog
Follow Us
RSS
Bookstore
